OpGen, Inc. (OPGN) Reports Q1 Loss Per Share of $5.61
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
OpGen Reports First Quarter Financial Results and Provides Business Update
June 17, 2015 4:05 PM EDTGAITHERSBURG, Md., June 17, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN), an early commercial-stage molecular testing and bioinformatics company, today reported financial results for the three months ended March 31, 2015. Highlights of the first quarter of 2015 and recent weeks include:
Completing a $17.1 million initial public offering (IPO) of common stock and warrants Strengthening the management team by adding Kevin Krenitsky, M.D. as president and Tim Dec as chief financial officer Launching the... More